The cell's waste accumulates like a clogged drain.
In the quiet language of inherited biology, three infants on different continents began their lives with a shared and previously unnamed burden — mutations in a gene called YKT6, whose role in human disease had never before been recognized. Researchers at Baylor College of Medicine and Boston Children's Hospital have now mapped this burden for the first time, tracing it to a disruption in autophagy, the cell's ancient system for clearing its own debris. The discovery is both a naming — rare disorders gain power when they are named — and a beginning, as science moves from recognition toward the longer work of healing.
- Three infants, unrelated and scattered across geographies, each began failing to thrive between four and six months old — their bodies quietly overwhelmed by a genetic fault no one had yet learned to read.
- Two of the children share not only an identical mutation but a common ancestral thread running through Kerala's Syrian Christian community, raising the possibility that millions of people worldwide may unknowingly carry the same variant.
- Fruit fly experiments confirmed what the patients' charts suggested — the Tyr185Cys mutation is the more destructive of the two variants, shortening lifespan and impairing movement, while also blocking the cellular recycling process that keeps brain and liver tissue alive.
- Two of the three children now face surveillance for hepatocellular carcinoma, a liver cancer risk layered on top of their neurological challenges — a reminder that a single defective gene can compromise multiple organs at once.
- Researchers are calling for carrier screening within affected communities and for more patients to be identified, knowing that the path from genetic discovery to therapeutic intervention requires a larger map of the disease than three children can provide.
Three infants, unrelated to one another, each began showing serious signs of illness between four and six months of age — failing to gain weight, missing developmental milestones, and presenting neurological problems that resisted easy explanation. Genetic analysis eventually revealed that all three carried mutations in a gene called YKT6, marking the first time variants in this gene have been linked to an inherited disorder. The finding was published in Genetics in Medicine by researchers at Baylor College of Medicine and Boston Children's Hospital.
Two of the children carried an identical mutation — a substitution at position 185 in the YKT6 protein, where tyrosine is replaced by cysteine. The third child had a similar change, but at position 64. All three experienced developmental and neurological difficulties, but the two with the position-185 mutation faced an additional threat: progressive liver disease and an elevated risk of hepatocellular carcinoma. Strikingly, both of those children belonged to the Syrian Christian community of Kerala, India — a diaspora of roughly five million people — and genetic evidence suggested the mutation traces back to a shared ancestor, meaning others in the community may carry it unknowingly.
To understand the disease mechanism, researchers used fruit flies, whose version of YKT6 closely mirrors the human gene. Flies carrying the equivalent of the Tyr185Cys variant lived shorter lives and showed severe movement impairment. Those with the Tyr64Cys equivalent fared better, confirming that the position-185 mutation is the more damaging of the two. The underlying cause involves autophagy — the cellular process by which worn-out proteins and molecules are broken down and recycled. YKT6 normally helps direct cellular waste toward lysosomes for disposal; when it fails, that waste accumulates, and the brain and liver, most dependent on efficient recycling, suffer progressive damage.
The researchers now recommend carrier screening for members of the Kerala Syrian Christian community and close cancer surveillance for children diagnosed with YKT6-related liver disease. Only three patients have been identified so far, and a fuller understanding of the disorder — and any path toward treatment — will depend on finding more. For now, a rare disease has been given a name and a genetic cause, and the harder work of turning that knowledge into medicine has begun.
Three infants, unrelated to one another, began showing signs of serious illness around the same time in their lives—between four and six months old. They failed to gain weight and reach developmental milestones. What their doctors eventually discovered, after careful genetic analysis, was that all three carried mutations in a gene called YKT6, a gene whose role in human disease had never before been documented. The finding, published in Genetics in Medicine and led by researchers at Baylor College of Medicine and Boston Children's Hospital, marks the first time YKT6 variants have been linked to an inherited genetic disorder.
The three patients presented a puzzle that required detective work across continents and disciplines. Two of them carried an identical mutation—a change at position 185 in the YKT6 protein where the amino acid tyrosine was replaced by cysteine. The third child had a similar tyrosine-to-cysteine swap, but at a different location in the protein, position 64. All three experienced developmental delays and neurological problems. But the two children with the position-185 mutation faced an additional burden: progressive liver disease and an elevated risk of hepatocellular carcinoma, the most common form of liver cancer.
What made the genetic pattern even more striking was the ancestry of two of the patients. Both children with the Tyr185Cys variant belonged to the Syrian Christian community of Kerala, India—a diaspora population estimated at roughly five million people worldwide. Genetic analysis suggested the mutation had arisen in a common ancestor before the community dispersed, meaning other members of this population might carry the same dangerous variant without knowing it.
To understand how these mutations caused disease, researchers turned to an unexpected model: the fruit fly. The fly version of the YKT6 gene is remarkably similar to the human version, and flies lacking functional copies of the gene died. When scientists introduced the human disease variants into flies, the results mirrored what was happening in the patients. Flies carrying the Tyr186Cys variant (equivalent to the human Tyr185Cys) lived significantly shorter lives and showed severe movement problems. Flies with the Tyr65Cys variant (equivalent to human Tyr64Cys) fared better, maintaining normal lifespan and locomotion. This suggested that the position-185 mutation was the more damaging of the two.
The mechanism underlying the disease involves a fundamental cellular process called autophagy—the cell's way of breaking down and recycling its own worn-out proteins and other molecules. YKT6 belongs to a family of proteins called SNAREs that act as molecular traffic controllers, directing cargo to the right cellular compartments. Specifically, YKT6 helps fuse autophagosomes, the cellular packages containing waste, with lysosomes, the cellular recycling centers. When YKT6 is defective, this fusion process stalls. The cell's waste accumulates, and the machinery of autophagy backs up like a clogged drain. In the brain and liver—the tissues most dependent on efficient cellular recycling—this blockage causes progressive damage.
The discovery opens several immediate clinical pathways. Researchers recommend that members of the Syrian Christian community of Kerala be offered carrier screening to identify who might pass the mutation to their children. Children diagnosed with YKT6-related liver disease should be monitored closely for signs of hepatocellular carcinoma. And the finding itself—that a single gene controls a process critical to both brain and liver health—may point toward future treatments. But much remains unknown. Only three patients have been identified so far. Understanding the full spectrum of the disease, and identifying which cellular pathways might be targeted therapeutically, will require finding and studying more affected individuals. For now, this rare disorder has a name and a genetic cause. The next chapter will be written by researchers working to turn that knowledge into treatment.
Citas Notables
This is the first time YKT6 has been linked to a genetically inherited disorder, providing a solid experimental foundation for future studies to better understand this new disease and develop therapies.— Dr. Hugo Bellen, Baylor College of Medicine
Children diagnosed with YKT6 liver disease will need to be screened for hepatocellular carcinoma.— Dr. Paula Hertel, Texas Children's Hospital
La Conversación del Hearth Otra perspectiva de la historia
Why does this particular gene matter so much to the brain and liver specifically?
Because both tissues are metabolically intense—they're constantly breaking down and rebuilding their own proteins. If the recycling system fails, waste piles up and cells start to die. The brain and liver are like the body's most demanding factories; they can't tolerate a broken assembly line.
The two children with the worse mutation—they're both from the same community in Kerala. Is that a coincidence?
No. Genetic analysis suggests the mutation arose once, in a common ancestor, before the community dispersed globally. So it's been passed down through families for generations. That's actually useful information—it means there are probably other carriers in that population who don't know it yet.
What does the fruit fly experiment actually tell us that we couldn't learn from just looking at the patients?
It shows us the mechanism. You can't easily study autophagy in a living child, but you can in a fly. The flies proved that the mutation specifically breaks the waste-recycling process, not something else. That's the difference between knowing a gene is involved and understanding why it causes disease.
So there's no treatment yet.
Not yet. But now that researchers know exactly which cellular process is broken, they can start looking for drugs that might fix it. The first step is always naming the disease and finding the cause. Everything else follows from that.
What happens to the three children who were diagnosed?
The two with liver involvement will need regular screening for cancer. All three will need ongoing neurological care. But they're also part of something larger now—their diagnosis is a map for other families. That matters.